| abstract |
A method of preventing, treating and / or ameliorating prostate disease or disorder associated with epithelial hyperplasia and / or fibrosis, which comprises administering an effective amount of a multikinase inhibitor to a subject in need thereof. Kinase inhibitors have a range of kinase inhibitory activity. Multikinase inhibitors are sunitinib, regorafenib, ponatinib, pazopanib, nintedanib and / or lenvatinib. Prostate disease or disorder is selected from the group consisting of benign prostatic hyperplasia and its associated lower urinary tract symptoms, ureteral and renal pelvis fibrosis, prostatic adenomas, and high-grade prostatic intraepithelial neoplasia in animals and humans. [Selection diagram] Fig. 4 |